Meeting
2019 ASCO Annual Meeting
Efficacy of platinum-pemetrexed combination chemotherapy in ALK+ non-small cell lung cancer refractory to second-generation ALK TKIs.
Authors
Jessica Jiyeong Lin
Massachusetts General Hospital, Harvard Medical School, Boston, MA
Jessica Jiyeong Lin , Adam Jacob Schoenfeld , Viola Weijia Zhu , Beow Y. Yeap , Emily Chin , Marguerite Rooney , Andrew J. Plodkowski , Subba Digumarthy , Ibiayi Dagogo-Jack , Justin F. Gainor , Sai-Hong Ignatius Ou , Gregory J. Riely , Alice Tsang Shaw
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9067)
DOI
10.1200/JCO.2019.37.15_suppl.9067
Abstract #
9067
Poster Bd #
390
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A phase 1b study of ensartinib in combination with platinum-based chemotherapy and bevacizumab in ALK-positive non-small cell lung cancer (NSCLC).
First Author: Kyle Concannon
Poster
2023 ASCO Annual Meeting
Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.
First Author: Li Zhang
Poster
2022 ASCO Annual Meeting
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.
First Author: Yuangyuan Zhao
Poster
2020 ASCO Virtual Scientific Program
Lorlatinib for advanced ALK and ROS1+ non-small cell lung cancer (NSCLC): Efficacy and treatment sequences in the IFCT-1803 LORLATU expanded access program (EAP) cohort.
First Author: Simon Baldacci